{"keywords": [{"value": "Hedge Funds", "rank": "1", "is_major": "Y", "name": "subject"}, {"value": "Valeant Pharmaceuticals International Inc", "rank": "2", "is_major": "Y", "name": "organizations"}, {"value": "ValueAct Capital Partners", "rank": "3", "is_major": "N", "name": "organizations"}, {"value": "Pearson, John Michael (1959- )", "rank": "4", "is_major": "N", "name": "persons"}, {"value": "Morfit, G Mason", "rank": "5", "is_major": "N", "name": "persons"}], "headline": {"kicker": "Deal Professor", "print_headline": "Valeant Stock Plunge Shows the Risk of Following the Leader", "content_kicker": "Deal Professor", "main": "Valeant Stock Plunge Shows the Risk of Following the Leader"}, "byline": {"original": "By STEVEN DAVIDOFF SOLOMON", "person": [{"middlename": "Davidoff", "organization": "", "lastname": "SOLOMON", "role": "reported", "firstname": "Steven", "rank": 1}]}, "web_url": "http://www.nytimes.com/2015/10/28/business/dealbook/valeant-stock-plunge-shows-risk-of-following-the-leader.html", "source": "The New York Times", "subsection_name": "DealBook", "slideshow_credits": null, "type_of_material": "News", "_id": "562fbfb338f0d8595b45ca11", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/10/28/business/28dealprofillo-web/28dealprofillo-web-thumbWide-v2.jpg"}, "type": "image", "width": 190, "url": "images/2015/10/28/business/28dealprofillo-web/28dealprofillo-web-thumbWide-v2.jpg"}, {"height": 599, "subtype": "xlarge", "legacy": {"xlargeheight": "599", "xlargewidth": "600", "xlarge": "images/2015/10/28/business/28dealprofillo-web/28dealprofillo-web-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/10/28/business/28dealprofillo-web/28dealprofillo-web-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnailheight": "75", "thumbnail": "images/2015/10/28/business/28dealprofillo-web/28dealprofillo-web-thumbStandard.jpg"}, "type": "image", "width": 75, "url": "images/2015/10/28/business/28dealprofillo-web/28dealprofillo-web-thumbStandard.jpg"}], "pub_date": "2015-10-28T00:00:00Z", "print_page": "8", "section_name": "Business Day", "word_count": "1180", "blog": [], "news_desk": "Business", "snippet": "The turmoil in Valeant Pharmaceuticals International shares reveals a dangerous tendency of hedge funds to engage in herd behavior when investing.", "document_type": "article", "abstract": "Steven Davidoff Solomon Deal Professor column points out sudden reversal in fortunes for Valeant Pharmaceuticals International underscores how hedge funds can sometimes participate in herd behavior, to detrimental results; notes Valeant was once darling of hedge funds, but suffered sharp drop in its stock price due to concerns about its practices; suggests that incident raises questions about what services hedge funds actually provide.", "lead_paragraph": "The turmoil in Valeant Pharmaceuticals International shares reveals a dangerous tendency of hedge funds to engage in herd behavior when investing."}